FDA chief to depart after Trump signed off on ousting him

FDA Leadership Transition Unfolds Amid Political Pressure

FDA chief to depart after Trump – The Food and Drug Administration (FDA) is undergoing a leadership change as its commissioner, Marty Makary, prepares to step down. According to three individuals with insider knowledge, the decision follows President Donald Trump’s approval of a plan to remove Makary from his position. This marks the latest shift in the agency’s top ranks, reflecting the administration’s ongoing efforts to reshape its regulatory direction.

Internal and External Pressures Mount

Makary has faced persistent pressure from within the Trump administration and external groups, including pharmaceutical companies and anti-abortion advocates. His resistance to approving flavored e-cigarettes has been a focal point of this tension. A faction of White House and Health and Human Services (HHS) officials, frustrated by the FDA’s internal discord and policy inconsistencies, has pushed for his removal. This effort gained momentum as the administration sought to consolidate control over key health initiatives.

Within the FDA, Makary oversaw a series of high-profile departures among senior leaders, creating a climate of uncertainty. His position as commissioner was increasingly seen as a point of contention, particularly regarding the agency’s handling of vaping products. While he aimed to streamline decision-making processes, his stance on youth-appealing e-cigarette flavors sparked criticism from both allies and adversaries.

“He doesn’t want to approve youth-appealing flavors, but has been forced to by the powers that be,” said a source close to Makary’s departure. This sentiment highlights the internal conflict he faced, where his personal convictions clashed with the administration’s priorities.

The decision to remove Makary came just a day before he was scheduled to appear before the Senate Appropriations Committee to discuss the FDA’s proposed budget. This timing underscores the strategic nature of the move, potentially amplifying the political impact of his departure. Politico was the first to report the news, signaling a broader narrative about the administration’s approach to regulatory oversight.

Replacing the FDA Chief

President Trump is expected to appoint Kyle Diamantas, currently serving as the deputy commissioner and head of the agency’s food program, as the acting FDA chief. While Diamantas is a seasoned official, his elevation to this role may signal a shift toward prioritizing food safety over broader public health initiatives. This choice also leaves the administration with the task of finding a permanent replacement, a process that requires Senate confirmation and could be delayed by the approaching midterm elections.

The FDA’s leadership vacuum adds to the existing challenges within the HHS department. The agency already lacks a permanent leader for the Centers for Disease Control and Prevention (CDC) and the surgeon general, who traditionally holds the title of the nation’s top physician. These vacancies have created logistical hurdles, as the administration scrambles to maintain operational continuity across its key health units.

Political Strategy Behind the Ouster

While some Trump advisors warned against removing another senior health official, fearing it might alienate the “Make America Healthy Again” base, others viewed Makary’s departure as inevitable. The administration’s internal factions have long debated the FDA’s role, with certain officials advocating for a more aggressive stance on policies like tobacco regulation and drug approvals. Makary’s resistance to these shifts, particularly on vaping products, was perceived as a barrier to alignment with the president’s goals.

Recent events have accelerated the push for Makary’s replacement. Last week, the FDA reversed its earlier position on flavored e-cigarettes, a decision that was seen as a compromise to appease the administration. This reversal, coupled with Makary’s ongoing efforts to defend his approach, has led to speculation about who orchestrated his removal. Some officials within the White House and HHS have hinted at a coordinated strategy to reset the agency’s leadership and strengthen ties with influential groups like the anti-abortion movement and pharmaceutical industry.

Impact on FDA’s Policy Agenda

Makary, a surgeon and author, had pledged to expedite FDA decisions on drugs, devices, and vaccines since his confirmation in March 2025. However, his tenure has been marked by controversy, particularly over the management of the drug approval process and his handling of tobacco regulations. Critics argue that his focus on consumer safety sometimes slowed down regulatory actions, while supporters credit him for maintaining rigorous standards.

The recent flap over flavored e-cigarettes has become a symbolic moment for the administration’s broader strategy. By forcing the FDA to reverse its stance, Trump has demonstrated his willingness to prioritize political considerations over scientific consensus. This approach has drawn mixed reactions, with some viewing it as necessary to align with the administration’s messaging on public health, while others see it as an erosion of the FDA’s independence.

Abortion Access and Regulatory Shifts

Another key development involves the FDA’s role in abortion policy. Susan B. Anthony Pro-Life America President Marjorie Dannenfelser met with White House officials to push for changes that would restrict the mailing of mifepristone, the abortion pill. This move, if implemented, could significantly affect access to medication abortion, which accounts for roughly two-thirds of all US abortions. The FDA’s regulation of such drugs has long been a battleground for political and ideological debates, and this meeting reflects the administration’s growing emphasis on tightening control over reproductive health policies.

The broader implications of these shifts are clear. The FDA’s decision to reverse its stance on flavored e-cigarettes and the potential changes to mifepristone regulations illustrate a pattern of aligning with the administration’s priorities, even at the expense of scientific caution. Makary’s departure also highlights the challenges of maintaining a cohesive policy agenda in a politically divided environment, where key decisions often hinge on the balance of power within the executive branch.

As the transition continues, the focus will shift to the new acting commissioner and the permanent successor yet to be named. The Senate confirmation process for this role could be a critical test for the administration, with the outcome potentially shaping the FDA’s trajectory in the months ahead. The agency’s recent reversals suggest that its future policies may be more responsive to political pressures, raising questions about the long-term stability of its regulatory framework.

Legacy of Leadership and Uncertainty

Makary’s time in office has been defined by both progress and controversy. While he implemented important reforms in certain areas, his leadership style and decisions on contentious issues like vaping and abortion have sparked debate. His departure leaves a void not only in terms of policy direction but also in the agency’s institutional memory. The incoming acting commissioner will face the dual challenge of stabilizing the FDA’s operations and navigating the complex landscape of public health priorities.

The transition reflects a larger trend of political influence over regulatory agencies under the Trump administration. With the FDA, CDC, and surgeon general positions all open, the health department is entering a period of flux. This uncertainty could impact the consistency of public health policies, as new leaders work to align with the administration’s vision. The ouster of Makary, however, is not just about personnel changes—it is a statement on the administration’s commitment to reshaping the FDA’s role in shaping national health decisions.